Valerie Arnold
Child & Adolescent Psychiatry · Memphis, TNNPI 1851358618
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Ironshore Pharmaceuticals Inc. accounts for 60.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $31,887 and has fallen 94.5% since, to $1,742 in 2025. Among child & adolescent psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $559.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$26K
- Supernus Pharmaceuticals, Inc.$8K
- Boehringer Ingelheim International GmbH$4K
- Vertical Pharmaceuticals, LLC$2K
- Boehringer Ingelheim$2K
- Shire North American Group Inc$1K
- plus $550 from 3 others
Across 465 payments — averaging $7812.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.4M
- Sage Therapeutics, LLC$622K
- Supernus Pharmaceuticals, Inc.$389K
- Corium, LLC$371K
- Arbor Pharmaceuticals, Inc.$193K
- Boehringer Ingelheim$155K
- plus $536K from 13 others
What the payments were for
- Consulting fees$12,41329%
- Speaking & faculty fees$20,94549%
- Travel & lodging$5,47113%
- Food & beverage$4,16410%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 37 | $26,226 |
| Supernus Pharmaceuticals, Inc. | 11 | $8,071 |
| Boehringer Ingelheim International GmbH | 4 | $3,613 |
| Vertical Pharmaceuticals, LLC | 1 | $1,600 |
| Boehringer Ingelheim | 11 | $1,575 |
| Shire North American Group Inc | 4 | $1,419 |
| Biogen | 5 | $412 |
| Tris Pharma Inc | 3 | $122 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$24,506
- RELEXXII$1,600
- MYDAYIS$1,406
- JORNAY PM$900
How this compares
$43,054 in reported general payments places this provider in the 95th percentile of 43 child & adolescent psychiatry providers in Tennessee.
See all child & adolescent psychiatry providers in Tennessee →
Other child & adolescent psychiatry in Memphis
- David StrubleMemphis$4K
- Anthony JacksonMemphis$771
- Adam ChanMemphis$379
- Alicia BarnesMemphis$201
- Ladoris WarrenMemphis$189
- Jonathan ShawMemphis$119
- Allison FordMemphis$86
- Andres Ramos HenriquezMemphis$73
- James MoseleyMemphis$34
- Kenneth PittmanChattanooga$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.